Company News

RocketVax has successfully completed another round of financing;  The development of the second-generation COVID-19 vaccine moves forward

6 February 2023

Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award

31 January 2023

Volker Thiel: "Wir planen noch besseren Corona-Impfschutz"

15 November 2022

RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines

23 September 2022

Burkhard Frey joins Rocketvax AG as Chief Commercial Officer

22 August 2022

SRF: Research on nasal corona vaccines raises hopes

22 August 2022

Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer

9 August 2022

Bilanz: Important Milestone

28 June 2022

Finanz und Wirtschaft: Doubts about the market for corona boosters

24 June 2022

RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models

9 June 2022

Swiss vaccine candidates enter clinical trial phase

28 March 2022

New Swiss COVID-19 vaccination as a nasal spray

28 March 2022

RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships

16 March 2022

Serbian state institutions and media representatives have been reporting on the recipient of the Nikola Tesla Award, Dr. Vladimir Cmiljanovic

18 November 2021

Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science

12 November 2021